Century Therapeutics Income Statement (2020-2026) | IPSC

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.06M1.40M2.22M0.52M1.72M0.10M0.15M0.27M0.85M0.77M0.79M4.17M109.16M
Operating items
Research & Development (Quarter)
18.93M19.55M21.80M21.20M24.49M25.90M25.59M24.90M22.73M22.79M22.30M23.42M27.22M27.23M29.38M26.58M26.86M0.01M19.70M17.11M
Selling, General & Administrative (Quarter)
4.09M6.28M6.18M7.30M8.25M8.06M8.24M8.90M8.23M8.99M8.59M8.74M8.31M8.35M7.75M8.41M7.80M6.83M0.96M6.58M
Other Operating Expenses (Quarter)
10.00M4.22M4.00M13.14M4.33M29.28M
Operating Expenses (Quarter)
23.02M25.83M27.97M38.49M32.75M33.96M33.83M33.80M35.18M35.77M44.03M32.16M35.53M35.58M41.46M34.99M34.66M36.12M20.65M23.68M
Operating Income (Quarter)
-23.02M-25.83M-27.97M-37.44M-31.35M-31.74M-33.31M-32.08M-35.08M-35.63M-43.76M-31.31M-34.76M-34.79M-37.28M74.18M-34.66M-36.12M-20.65M-23.68M
EBIT (Quarter)
-23.02M-25.83M-27.97M-37.44M-31.35M-31.74M-33.31M-32.08M-35.08M-35.63M-43.76M-31.31M-34.76M-34.79M-37.28M74.18M-34.66M-36.12M-20.65M-23.68M
Non-operating items
Interest & Investment Income (Quarter)
0.71M1.41M2.62M3.06M3.49M3.51M3.24M3.58M3.31M2.88M2.42M2.01M1.60M1.31M2.02M
Other Non Operating Income (Quarter)
-0.25M0.14M-0.18M-0.06M0.01M-0.02M4.44M-0.19M-0.19M0.01M-0.01M0.01M-0.01M0.25M-0.43M-0.04M0.11M0.10M-0.18M0.02M
Non Operating Income (Quarter)
0.38M1.01M1.66M2.02M2.74M3.50M3.50M3.25M3.57M3.56M2.99M2.38M2.12M1.70M1.41M2.04M
Net income details
EBT (Quarter)
-23.27M-26.01M-28.15M-37.50M-30.97M-30.72M-31.65M-30.06M-32.34M-32.13M-40.27M-28.06M-31.18M-31.23M-34.30M76.56M-32.54M-34.42M-9.55M-90.91M
Tax Provisions (Quarter)
0.02M0.02M0.03M0.03M1.21M0.95M0.59M-0.87M0.00M0.02M-0.01M1.38M
Profit After Tax (Quarter)
-23.27M-26.01M-28.78M-37.51M-30.99M-30.92M-30.54M-31.26M-33.29M-32.82M-37.98M-28.06M-31.21M-31.23M-36.51M76.54M-32.54M-34.42M-19.46M-21.64M
Income from Continuing Operations (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.67M76.56M-32.54M-34.42M-9.55M-90.91M
Consolidated Net Income (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.67M76.56M-32.54M-34.42M-9.55M-90.91M
Income towards Parent Company (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.67M76.56M-32.54M-34.42M-9.55M-90.91M
Net Income towards Common Stockholders (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.67M76.56M-32.54M-34.42M-9.55M-90.91M
Additional items
EPS (Basic) (Quarter)
-1.93-0.48-0.87-0.66-0.54-0.53-0.55-0.53-0.56-0.55-0.66-0.45-0.38-0.37-0.450.89-0.38-0.40-0.11-0.47
EPS (Diluted) (Quarter)
-1.93-0.48-0.87-0.66-0.54-0.53-0.55-0.53-0.56-0.55-0.68-0.45-0.38-0.37-0.450.89-0.38-0.40-0.11-0.47
Shares Outstanding (Quarter)
12.04M54.47M32.39M57.05M57.69M57.97M57.76M58.61M59.25M59.45M59.31M62.30M82.09M84.70M78.65M86.02M86.24M86.46M86.56M193.47M
Shares Outstanding (Diluted) (Quarter)
12.04M54.47M32.39M57.05M57.69M57.97M57.76M58.61M59.25M59.45M57.76M62.30M82.09M84.70M78.65M86.10M86.24M86.46M86.56M193.47M
EBITDA (Quarter)
-23.02M-25.83M-27.97M-37.44M-31.35M-31.74M-33.31M-32.08M-35.08M-35.63M-43.76M-31.31M-34.76M-34.79M-37.28M74.18M-34.66M-36.12M-20.65M-23.68M
Interest Expenses (Quarter)
0.32M0.32M0.01M0.24M0.33M0.37M0.31M0.40M8.05M0.51M-0.05M81.86M94.51M87.00M192.23M0.40M24.12M21.44M0.01M69.25M
Tax Rate (Quarter)
-0.04%-0.06%-0.08%-0.10%-4.02%-2.94%-1.84%2.16%0.00%-0.07%0.03%-4.01%